Assmus F. Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside. PLoS Neglected Tropical Diseases Vol.16 No.3 (2022). doi:10.1371/journal.pntd.0010219 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/86061
Title
Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside
To accelerate the progress towards onchocerciasis elimination, a macrofilaricidal drug that kills the adult parasite is urgently needed. Emodepside has shown macrofilaricidal activity against a variety of nematodes and is currently under clinical development for the treatment of onchocerciasis. The aims of this study were i) to characterize the population pharmacokinetic properties of emodepside, ii) to link its exposure to adverse events in healthy volunteers, and iii) to propose an optimized dosing regimen for a planned phase II study in onchocerciasis patients.
